Drugs for Neurodermatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 47)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Lidocaine |
Approved, Vet_approved |
Phase 4 |
|
137-58-6 |
3676 |
Synonyms:
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-2ETN-2MePhAcN
a-Diethylamino-2,6-dimethylacetanilide
ALGRX 3268
ALGRX-3268
ALPHACAINE
alpha-Diethylamino-2,6-dimethylacetanilide
ANESTACON
Astrazeneca brand OF lidocaine
Dalcaine
Dentipatch
Dilocaine
EMBOLEX
IONTOCAINE
Jenapharm brand OF lidocanine hydrochloride
L-Caine
Lidocaina
Lidocaína
LIDOCAINE
Lidocaine carbonate
Lidocaine carbonate (2:1)
Lidocaine hydrocarbonate
Lidocaine hydrochloride
Lidocaine monoacetate
Lidocaine monohydrochloride
|
Lidocaine monohydrochloride, monohydrate
Lidocaine sulfate (1:1)
Lidocainum
LIDOCATON
Lidoderm
LIDOPEN
Lignocaine
LIGNOCAINE HCL
LIGNOSTAB
LMX 4
Novocol brand OF lidocaine hydrochloride
NSC-40030
Octocaine
ORAQIX
Strathmann brand OF lidocaine hydrochloride
VAGISIL
Xylesthesin
Xylocaine
Xylocaine®
Xylocitin
XYLODASE
Xyloneural
XYLOTOX
ZTLIDO
Α-diethylamino-2,6-dimethylacetanilide
|
|
2 |
|
Antirheumatic Agents |
|
Phase 4 |
|
|
|
3 |
|
Evening Primrose |
|
Phase 4 |
|
|
|
4 |
|
Antimetabolites |
|
Phase 4 |
|
|
|
5 |
|
Hypolipidemic Agents |
|
Phase 4 |
|
|
|
6 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 4 |
|
|
|
7 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
8 |
|
Analgesics, Non-Narcotic |
|
Phase 4 |
|
|
|
9 |
|
Analgesics |
|
Phase 4 |
|
|
|
10 |
|
Lipid Regulating Agents |
|
Phase 4 |
|
|
|
11 |
|
Olive |
|
Phase 4 |
|
|
|
12 |
|
Linoleate |
|
Phase 4 |
|
|
|
13 |
|
Dermatologic Agents |
|
Phase 4 |
|
|
|
14 |
|
Anti-Arrhythmia Agents |
|
Phase 4 |
|
|
|
15 |
|
Sodium Channel Blockers |
|
Phase 4 |
|
|
|
16 |
|
Anesthetics, Local |
|
Phase 4 |
|
|
|
17 |
|
Anesthetics |
|
Phase 4 |
|
|
|
18 |
|
Diuretics, Potassium Sparing |
|
Phase 4 |
|
|
|
19 |
|
Evening primrose oil |
Investigational, Nutraceutical |
Phase 4 |
|
308064-97-3 |
|
Synonyms:
Oenothera biennis (evening primrose) oil
Oenothera biennis (evening primrose) seed extract
Oenothera biennis l. oil
Oenothera biennis seed extract
Oenothera biennis seed oil
Oenothera lamarckiana l. oil
Oenothera muricata seed oil
|
Oenothera oil
Oenothera pycnocarpa seed oil
Oenotherae biennis oleum
Oils, glyceridic, evening primrose
Oleum oenotherae erythrospinae
Primrose oil
|
|
20 |
|
Crofelemer |
Approved |
Phase 3 |
|
33507-63-0, 148465-45-6 |
36511 44359816 |
Synonyms:
(2S)-2-{[(2R)-2-({[(2S)-1-[(2S)-6-amino-2-({[(2R)-1-[(2S)-2-amino-5-carbamimidamidopentanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)hexanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-1-hydroxy-4-(C-hydroxycarbonimidoyl)butylidene]amino}-N-[(1R)-1-{[(1R)-1-[({[(1R)-1-{[(1S)-1-(C-hydroxycarbonimidoyl)-3-(methylsulfanyl)propyl]-C-hydroxycarbonimidoyl}-3-methylbutyl]-C-hydroxycarbonimidoyl}methyl)-C-hydroxycarbonimidoyl]-2-phenylethyl]-C-hydroxycarbonimidoyl}-2-phenylethyl]pentanediimidate
(2S)-2-{[(2R)-2-({[(2S)-1-[(2S)-6-amino-2-({[(2R)-1-[(2S)-2-amino-5-carbamimidamidopentanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)hexanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-1-hydroxy-4-(C-hydroxycarbonimidoyl)butylidene]amino}-N-[(1R)-1-{[(1R)-1-[({[(1R)-1-{[(1S)-1-(C-hydroxycarbonimidoyl)-3-(methylsulphanyl)propyl]-C-hydroxycarbonimidoyl}-3-methylbutyl]-C-hydroxycarbonimidoyl}methyl)-C-hydroxycarbonimidoyl]-2-phenylethyl]-C-hydroxycarbonimidoyl}-2-phenylethyl]pentanediimidate
(2S)-2-{[(2R)-2-({[(2S)-1-[(2S)-6-amino-2-({[(2R)-1-[(2S)-2-amino-5-carbamimidamidopentanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)hexanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-1-hydroxy-4-(C-hydroxycarbonimidoyl)butylidene]amino}-N-[(1R)-1-{[(1R)-1-[({[(1R)-1-{[(1S)-1-(C-hydroxycarbonimidoyl)-3-(methylsulphanyl)propyl]-C-hydroxycarbonimidoyl}-3-methylbutyl]-C-hydroxycarbonimidoyl}methyl)-C-hydroxycarbonimidoyl]-2-phenylethyl]-C-hydroxycarbonimidoyl}-2-phenylethyl]pentanediimidic acid
[<sup>125</sup>I]-SP|[<sup>125</sup>I]-substance P
[<sup>3</sup>H]-SP|[<sup>3</sup>H]-substance P
Arg-pro-lys-pro-GLN-GLN-phe-phe-gly-leu-met-NH2
CROFELEMER
Euler gaddum substance p
Euler-gaddum substance p
FULYZAQ
Fulyzaq®|SP-303
Hypothalamic substance p
|
MYTESI
NP-303
P, Euler-gaddum substance
P, Hypothalamic substance
P, Substance
PROVIR
SP(1-11)
SP-303
Substance p, euler-gaddum
Substance p, hypothalamic
TRN-002
VIREND
|
|
21 |
|
Nalbuphine |
Approved |
Phase 2, Phase 3 |
|
20594-83-6 |
5311304 |
Synonyms:
Hydrochloride, nalbuphine
Intapan
Nalbufina
NALBUPHIN
NALBUPHINE
Nalbuphine hydrochloride
Nalbuphine serb
Nalbuphine serb brand
|
Nalbuphinum
N-Cyclobutylmethyl-4,5a-epoxy-3,6a,14-morphinantriol
N-Cyclobutylmethyl-4,5alpha-epoxy-3,6alpha,14-morphinantriol
N-Cyclobutylmethyl-4,5α-epoxy-3,6α,14-morphinantriol
Nubain
Nubain®
SERB brand OF nalbuphine
Serb, nalbuphine
|
|
22 |
|
Serlopitant |
Investigational |
Phase 3 |
|
860642-69-9 |
23653789 |
Synonyms:
compound 17 (Jiang <i>et al.</i> 2009)|VPD-737
MK-0594
|
|
|
23 |
|
Calcineurin Inhibitors |
|
Phase 3 |
|
|
|
24 |
|
Neurotransmitter Agents |
|
Phase 3 |
|
|
|
25 |
|
Neurokinin-1 Receptor Antagonists |
|
Phase 3 |
|
|
|
26 |
|
Neurokinin A |
|
Phase 3 |
|
86933-74-6 |
55582 |
Synonyms:
Neurokinin alpha
Neuromedin L
|
|
|
27 |
|
Analgesics, Opioid |
|
Phase 2, Phase 3 |
|
|
|
28 |
|
Narcotics |
|
Phase 2, Phase 3 |
|
|
|
29 |
|
Apremilast |
Approved, Investigational |
Phase 2 |
|
608141-41-9 |
10151715 11561674 |
Synonyms:
APREMILAST
APRÉMILAST
APREMILASTUM
CC 10004
CC10004
|
CC-10004
CC-10004|Otezla®
N-{2-[(1S)-1-(3-ETHOXY-4-METHOXYPHENYL)-2-(METHYLSULFONYL)ETHYL]-1,3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YL}ACETAMIDE
OTEZLA
|
|
30 |
|
Abrocitinib |
Approved, Investigational |
Phase 2 |
|
1622902-68-4 |
78323835 |
Synonyms:
ABROCITINIB
Cibinqo®|compound 25 [PMID: 29298069]|PF-04965842|PF04965842
|
N-[3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]propane-1-sulfonamide
PF-04965842
|
|
31 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
32 |
|
Immunoglobulins |
|
Phase 2 |
|
|
|
33 |
|
Antibodies, Monoclonal |
|
Phase 2 |
|
|
|
34 |
|
Antibodies |
|
Phase 2 |
|
|
|
35 |
|
Phosphodiesterase Inhibitors |
|
Phase 2 |
|
|
|
36 |
|
Phosphodiesterase 4 Inhibitors |
|
Phase 2 |
|
|
|
37 |
|
Histamine H1 Antagonists |
|
Phase 2 |
|
|
|
38 |
|
Histamine Antagonists |
|
Phase 2 |
|
|
|
39 |
|
Immunosuppressive Agents |
|
Phase 2 |
|
|
|
40 |
|
Protein Kinase Inhibitors |
|
Phase 2 |
|
|
|
41 |
|
Pharmaceutical Solutions |
|
Phase 2 |
|
|
|
42 |
|
Citalopram |
Approved |
|
|
59729-32-7, 59729-33-8 |
2771 |
Synonyms:
[<sup>3</sup>H]-citalopram
Akarin
Bonitrile
Celapram
Celexa
Celexa®|Cipramil®|LU-10171B
Celius
Ciazil
Cilift
Cipram
CIPRAMIL
Ciprapine
Citabax
Citadur
Citalec
Citalopram
Citalopram hydrobromide
Citalopramum
Citalopramum [INN-Latin]
Citol
Citopam
Citox
|
Citrol
Cytalopram
Dalsan
Elopram
Escitalopram
Escitalopram oxalate
Humorup
Lexapro
LU 10-171-B
LU-10-171-B
Nitalapram
Oropram
PAXORAN
Pramcit
Recital
Seropram
Talam
Talohexal
Temperax
Vodelax
Zentius
Zetalo
|
|
43 |
|
Dexetimide |
Withdrawn |
|
|
21888-98-2 |
30843 |
Synonyms:
(+)-BENZETIMIDE
(+)-benzetimide|R 16470|Tremblex®
Dexetimida
DEXETIMIDE
|
Dexetimidum
R 16470
R-16470 [AS HYDROCHLORIDE]
TREMBLEX
|
|
44 |
|
Psychotropic Drugs |
|
|
|
|
|
45 |
|
Antidepressive Agents |
|
|
|
|
|
46 |
|
Serotonin Uptake Inhibitors |
|
|
|
|
|
47 |
|
Serotonin |
Investigational, Nutraceutical |
|
|
50-67-9 |
5202 |
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5 Hydroxytryptamine
5-HT
5-HT|serotonin
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
5-Hydroxy-tryptamine
|
Antemovis
DS Substance
Enteramin
Enteramine
Hippophaine
Hydroxytryptamine
SEROTONIN
Serotonine
sérotonine
Thrombocytin
Thrombotonin
|
|
Interventional clinical trials:
(show all 26)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Prospective Clinical Trial to Assess the Efficacy and Safety of EPOGAM 1000 in Patients With Atopic Dermatitis (Explorative Pilot Study) |
Completed |
NCT00878670 |
Phase 4 |
EPOGAM 1000 |
2 |
The Use of Local Anesthetic in Intralesional Corticosteroid Injections; A Randomized, Double Blind Controlled Trial |
Completed |
NCT03630198 |
Phase 4 |
Corticosteroid with lidocaine;Corticosteroid with normal saline |
3 |
Prospective, Controlled Three-Armed Study About Effectiveness and Compatibility of Silver-Containing Textiles for Treatment of Acute Neurodermatitis |
Completed |
NCT00196430 |
Phase 3 |
corticosteroid |
4 |
A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable |
Completed |
NCT04183335 |
Phase 3 |
Dupilumab SAR231893;Placebo;Moisturizers;Low to medium potent topical corticosteroids;Topical calcineurin inhibitors |
5 |
A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable |
Completed |
NCT04202679 |
Phase 3 |
Dupilumab SAR231893;Placebo;Moisturizers;Low to medium potent topical corticosteroids;Topical calcineurin inhibitors |
6 |
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Prurigo Nodularis |
Completed |
NCT03677401 |
Phase 3 |
5mg Serlopitant Tablets;Placebo Tablets |
7 |
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Prurigo Nodularis |
Completed |
NCT03546816 |
Phase 3 |
5mg Serlopitant Tablets;Placebo Tablets |
8 |
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis |
Completed |
NCT04501679 |
Phase 3 |
Nemolizumab;Placebo |
9 |
An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients |
Completed |
NCT02174432 |
Phase 2, Phase 3 |
nalbuphine HCl ER |
10 |
A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients |
Completed |
NCT02174419 |
Phase 2, Phase 3 |
nalbuphine HCl ER tablets 90 mg BID;nalbuphine HCl ER tablets 180 mg BID;Placebo tablets BID |
11 |
A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo Nodularis |
Recruiting |
NCT05052983 |
Phase 3 |
Nemolizumab;Placebo |
12 |
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis |
Active, not recruiting |
NCT04501666 |
Phase 3 |
Nemolizumab 30 mg;Placebo |
13 |
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis |
Enrolling by invitation |
NCT04204616 |
Phase 3 |
Nemolizumab |
14 |
Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis |
Unknown status |
NCT03576287 |
Phase 1, Phase 2 |
Apremilast Oral Product |
15 |
A Randomized, Placebo-controlled, Double-blind Study to Scrutinize the Efficacy of Secukinumab in Patients With Moderate to Severe Atopic Dermatitis |
Completed |
NCT03568136 |
Phase 2 |
Secukinumab 300 mg;Placebo |
16 |
KPL-716-C202: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Pilot Study to Investigate the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Diseases Characterized by Chronic Pruritus |
Completed |
NCT03858634 |
Phase 2 |
KPL-716;Placebo |
17 |
An Open Label, Single Center Study to Assess the Safety and Efficacy of a 24 Week Treatment Course of CC-10004 in Adults With Recalcitrant Nodularis |
Completed |
NCT00869089 |
Phase 2 |
CC-10004 |
18 |
Efficacy, Safety, and Tolerability of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin |
Completed |
NCT05038982 |
Phase 2 |
Abrocitinib |
19 |
A Randomized, Double-Blind, Placebo-Controlled, Study of Neurokinin-1 Receptor Antagonist Serlopitant in Subjects With Prurigo Nodularis |
Completed |
NCT02196324 |
Phase 2 |
serlopitant;Placebo |
20 |
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis |
Recruiting |
NCT05061693 |
Phase 2 |
INCB054707;Placebo |
21 |
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects With Prurigo Nodularis |
Active, not recruiting |
NCT03816891 |
Phase 2 |
vixarelimab;Placebo |
22 |
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single Dose Study to Assess the Safety, Pharmacokinetics, and Clinical Effect of CDX-0159 in Patients With Prurigo Nodularis |
Recruiting |
NCT04944862 |
Phase 1 |
Normal saline |
23 |
Double-blind, Vehicle-controlled, Phase I Study to Evaluate Safety and Efficacy of a 0.3% and 1% Topical Formulation of KM-001 for Management of Moderate to Severe Pruritus in Adult Patients With Lichen Simplex Chronicus (LSC) |
Recruiting |
NCT05454462 |
Phase 1 |
IMP Application KM-001 |
24 |
Transcriptomic Landscape of T Lymphocytes of Atopic Dermatitis, Atopic Prurigo Nodularis (of Besnier) and Non-atopic Prurigo Nodularis (of Hyde) Using Single Cell RNA-sequencing |
Unknown status |
NCT04681300 |
|
|
25 |
Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis |
Unknown status |
NCT00532519 |
|
citalopram (cipralex) |
26 |
Diagnostic Accuracy of "Three Rings Vulvoscopy" for Detection of Vulvar Dermatosis |
Completed |
NCT02732145 |
|
|
Cochrane evidence based reviews: neurodermatitis
|